Curious about Edwards Lifesciences (EW) Q2 Performance? Explore Wall Street Estimates for Key Metrics

Wall Street analysts forecast Edwards Lifesciences (EW) to report Q2 EPS of $0.62, an 11.4% year-over-year decline, on revenues of $1.49 billion, down 8.9%, with the consensus EPS estimate stable over 30 days. Despite these overall top-line pressures, segment analysis indicates strong growth in Transcatheter Mitral and Tricuspid Therapies (+56.5% to $129.87M) and modest gains in Transcatheter Aortic Valve Replacement (+5.7% to $1.10B), alongside robust international sales, particularly in Japan (+20.3%). This mixed outlook, featuring declining headline figures but strong growth in key emerging product lines and international markets, positions EW with a Zacks Rank #2 (Buy), suggesting potential near-term outperformance despite recent share underperformance against the S&P 500.

Analysis

Wall Street forecasts for Edwards Lifesciences' (EW) upcoming quarter present a mixed outlook, characterized by significant year-over-year declines in headline figures but underlying strength in key growth areas. Analysts project a decrease in total revenue of 8.9% to $1.49 billion and a drop in earnings per share of 11.4% to $0.62. These negative top-line expectations contrast sharply with robust performance forecasts in specific product and geographic segments. Notably, the Transcatheter Mitral and Tricuspid Therapies division is expected to see sales surge by 56.5%, while the core Transcatheter Aortic Valve Replacement segment is anticipated to grow by a solid 5.7%. Conversely, the Surgical Structural Heart business is projected to contract by 1.9%. Geographically, international markets are a key source of strength, with Japan sales forecast to grow 20.3% and total sales outside the U.S. expected to rise 9.3%, outpacing the 6% growth projected for the United States. The stability of the consensus EPS estimate over the past 30 days suggests analysts have already factored in this complex dynamic, and despite the stock's recent 3.6% gain underperforming the S&P 500, the company holds a Zacks Rank #2 (Buy), indicating potential for near-term outperformance.

Key Decisions for Investors

• Investors should look beyond the headline year-over-year declines in revenue and EPS, focusing instead on the execution within high-growth segments like Transcatheter Mitral and Tricuspid Therapies as a primary indicator of the company's future trajectory.
• Monitor the performance of international sales, particularly in Japan where growth is forecast at over 20%, as this geographic strength is a critical offset to the contracting Surgical Structural Heart business.
• Given the conflicting signals of negative top-line forecasts versus strong underlying segment growth and a 'Buy' rating, the upcoming earnings report will be pivotal; any outperformance in the high-growth divisions or the core TAVR segment could serve as a significant positive catalyst for the stock.